Gene-Editing Pick From Cathie Wood Is Up 41% YTD – Worth the Risk?

Cathie Wood, founder and CEO of Ark Invest, has built a reputation for identifying companies poised to disrupt markets through cutting-edge innovation. Her investment thesis centers on emerging technologies with transformative potential, particularly in biotechnology and gene editing—a therapeutic frontier that could fundamentally reshape how medicine treats previously incurable diseases. Intellia Therapeutics, a gene-editing specialist currently ranking 25th in Ark Invest’s portfolio, exemplifies this investment philosophy. Year-to-date, the stock has already delivered a 41% return. But can this momentum sustain itself, and does it deserve a place in your portfolio?

Why This Cathie Wood Stock Pick Gained Momentum

Intellia Therapeutics develops gene-editing therapies targeting rare genetic disorders. The company’s two lead programs—nex-z and lonvo-z—represent its most advanced clinical candidates, yet both have faced significant regulatory hurdles that defined their recent trajectory.

The turning point came when the FDA lifted clinical restrictions on one of nex-z’s two phase 3 studies. Previously, both studies had been halted following an adverse safety event in late 2025. The regulatory clearance, though applied to only one trial, signaled potential progress and reignited investor interest. While the second nex-z trial remains under restrictions, the removal of limitations on the first study suggests regulatory pathways may be opening. This development triggered the stock’s recovery from its earlier losses, converting a period of uncertainty into cautious optimism among market participants.

The Market Opportunity Behind Intellia Therapeutics

Understanding Intellia’s upside potential requires examining the addressable markets its candidates could capture. The company’s therapeutic targets represent substantial patient populations with genuine medical need and limited treatment options.

Nex-z, for instance, targets transthyretin amyloidosis—a progressive disease causing cardiovascular complications. Globally, approximately 50,000 patients suffer from the hereditary variant, while between 200,000 and 500,000 have the acquired form, which typically emerges in older populations. Currently, no cure exists. If successful, nex-z could address a $16.8 billion market opportunity by 2030.

Intellia’s other lead candidate, lonvo-z, targets hereditary angioedema, a rare condition characterized by unpredictable swelling episodes. With 150,000 estimated patients worldwide, this market represents an addressable opportunity valued at approximately $6.3 billion by 2030. Both market projections underscore why Cathie Wood’s investment thesis sees potential in Intellia’s pipeline.

Significant Risks Remain the Key Concern

Despite compelling market dynamics, gene-editing biotechs operate in an inherently uncertain environment. Clinical development carries substantial execution risk—regulatory setbacks, failed trials, or safety concerns can rapidly destroy shareholder value. Intellia’s recent clinical hold demonstrates this vulnerability firsthand.

Beyond clinical challenges lies a broader commercial reality. Even approved gene-editing medicines have struggled to achieve widespread adoption. The complexity of administration, elevated manufacturing costs, and reimbursement uncertainties create formidable barriers to market penetration. This means that peak sales potential, even for successful therapies, may fall short of theoretical market projections.

Furthermore, the regulatory landscape remains unpredictable. A single adverse event or unexpected safety signal could trigger another clinical hold, potentially derailing both programs simultaneously. For risk-averse investors, these considerations present meaningful reasons for caution.

Should You Follow Cathie Wood Into This Stock?

While Cathie Wood’s track record of identifying innovative companies commands respect, Intellia Therapeutics remains a fundamentally risky investment. The combination of clinical uncertainties, regulatory volatility, and execution challenges means this stock suits only investors with elevated risk tolerance and extended time horizons.

The recent 41% gain may tempt some investors to chase momentum. However, potential investors should recognize that gene-editing stocks frequently experience sharp reversals. Before committing capital, carefully assess whether you can withstand significant downside scenarios. For most conservative investors, the prudent approach involves waiting for more evidence of sustained clinical progress and regulatory stability before establishing a position.